focus -WSS

focus

author：knowledge 2025-09-03 12:07:43 - browse：2

Adam's take main illustration — Molly Ferguson/STAT

Behind the stellar commercial launch of Amylyx Pharmaceuticals’ treatment for ALS lies an uncomfortable question: Does early success of the drug, called Relyvrio, make it more complicated, perhaps impossible, to pull it from the market if we find out next year that it doesn’t work?

On Monday night, Amylyx said Relyvrio sales totaled $22 million in 2022 — a period that covers slightly more than one calendar quarter given the drug’s U.S. approval last September. The company said approximately 1,300 ALS patients were on Relyvrio at the end of December, and it expects that number to at least double by the end of the first quarter.

“We’re probably going to double, closer to triple, our revenue in Q1,” said James Frates, Amylyx’s chief financial officer, speaking on Monday night’s conference call.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Canadians with cystic fibrosis outlive Americans by a decade

hotspot

WSS

Change Healthcare cyberattack shows risk of industry consolidation

Color Health wants to make cancer screenings convenient

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

Redefining sustainability for the pharmaceutical industry

Readout Newsletter: Beam, Prozac, "TechBio" and more

Pfizer is about to make a big push in cancer. Will investors listen?

knowledge

focus

knowledge

United colonoscopy coverage change 'may cost lives,' doctors say

The wait for US passports is creating travel purgatory and snarling summer plans

In Memoriam: Notable people who died in 2023

Pfizer is about to make a big push in cancer. Will investors listen?

United colonoscopy coverage change 'may cost lives,' doctors say

Study fuels hope CAR

The high cost of giving birth even with insurance

Pfizer is about to make a big push in cancer. Will investors listen?

Guidelines to prevent youth baseball injuries need more muscle

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

knowledge

'Screen and refer' systems are hurting patients

AstraZeneca lung cancer study comes in below expectations

Children’s Hospital revives plan for pedestrian bridge

Skip the lead apron during X

UpToDate has a racism problem: Dr. Stanley Goldfarb

Undocumented workers face uncertainty as immigration law takes effect in Florida

focus

hotspot

hotspot

Wikipedia